According to the complaint, during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the science behind Abeona's proposed gene therapy treatment for Sanfilippo syndrome is unviable; (2) Steven H. Rouhandeh, Abeona's Executive Chairman and Principal Executive Officer, previously worked for a biotech promoter who was convicted of securities fraud and involved in manipulating biotech stocks; and (3) as a result, Defendants' statements about Abeona's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On December 12, 2016, analyst firm Mako Research published a report asserting, among other things, that Abeona's science underpinning its gene therapy approach is unviable and that Rouhandeh previously worked in a position of authority at D. Blech & Co.—a firm named after nowconvicted felon David Blech.
If you suffered a loss in Abeona you have until February 14, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/abeona-therapeutics-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/abeo-upcoming-deadline-the-law-offices-of-vincent-wong-reminds-investors-of-a-class-action-involving-abeona-therapeutics-inc-and-a-lead-plaintiff-deadline-of-february-14-2017-300405613.html
SOURCE The Law Offices of Vincent Wong